echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Saiyuan Bio completed nearly 100 million yuan in financing to facilitate the clinical research of iPSC-derived ready-to-use cell drugs

    Saiyuan Bio completed nearly 100 million yuan in financing to facilitate the clinical research of iPSC-derived ready-to-use cell drugs

    • Last Update: 2022-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 16, Saiyuan Biotechnology (Hangzhou) Co.


    Headquartered in Hangzhou, China, Saiyuan Bio focuses on the differentiation of engineered pluripotent stem cells (iPSCs) into innate immune cells (such as macrophages, natural killer cells, etc.


    ▲Saiyuan Bio’s pipeline under development (Image source: Saiyuan Bio’s official website)

    According to the official website, Saiyuan Bio has established 6 R&D pipelines for hematological tumors and solid tumors, all of which are in the preclinical stage


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.